Expression of the retinoblastoma-related gene Rb2/p130 in the pathogenesis of serous carcinoma of the ovary

Michael J. Worley, Charles N. Landen, Brian Slomovitz, Anais Malpica, Shana L. Palla, Pedro T. Ramirez

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Objective: The purpose of this study was to evaluate the immunohistochemical Rb2/p130 expression in a series of benign, borderline, and malignant ovarian tumors. Study Design: Seventy-six operative specimens were analyzed. Frequencies and percents were calculated for variables by each of the 5 disease stage groups in increasing severity and again for the disease stage groups collapsed into benign (serous cystadenoma or endosalpingosis), low-grade [serous borderline tumors (SBT) or low-grade serous carcinoma (LGSC)] and high-grade serous carcinoma. Results: There was no loss of expression in benign serous cystadenomas (0/18). Ten percent of SBT's (2/20), 47% of LGSC's (9/19), and 16% of HGSC's (3/16) had loss of expression. There was a significant difference in the expression during the progression from cystadenoma to SBT to LGSC. Conclusions: Loss of Rb2/p130 expression is a rare event in benign cystadenoma. The progression to LGSC is associated with a decrease in gene expression.

Original languageEnglish (US)
Pages (from-to)509-511
Number of pages3
JournalApplied Immunohistochemistry and Molecular Morphology
Volume18
Issue number6
DOIs
StatePublished - Dec 2010
Externally publishedYes

Fingerprint

Retinoblastoma Genes
Serous Cystadenoma
Ovary
Carcinoma
Cystadenoma
Neoplasms
Gene Expression

Keywords

  • ovarian cancer
  • ovary
  • Rb2/p130
  • retinoblastoma

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Medical Laboratory Technology
  • Histology

Cite this

Expression of the retinoblastoma-related gene Rb2/p130 in the pathogenesis of serous carcinoma of the ovary. / Worley, Michael J.; Landen, Charles N.; Slomovitz, Brian; Malpica, Anais; Palla, Shana L.; Ramirez, Pedro T.

In: Applied Immunohistochemistry and Molecular Morphology, Vol. 18, No. 6, 12.2010, p. 509-511.

Research output: Contribution to journalArticle

Worley, Michael J. ; Landen, Charles N. ; Slomovitz, Brian ; Malpica, Anais ; Palla, Shana L. ; Ramirez, Pedro T. / Expression of the retinoblastoma-related gene Rb2/p130 in the pathogenesis of serous carcinoma of the ovary. In: Applied Immunohistochemistry and Molecular Morphology. 2010 ; Vol. 18, No. 6. pp. 509-511.
@article{6fc59883816f452a875ecbfa079306fd,
title = "Expression of the retinoblastoma-related gene Rb2/p130 in the pathogenesis of serous carcinoma of the ovary",
abstract = "Objective: The purpose of this study was to evaluate the immunohistochemical Rb2/p130 expression in a series of benign, borderline, and malignant ovarian tumors. Study Design: Seventy-six operative specimens were analyzed. Frequencies and percents were calculated for variables by each of the 5 disease stage groups in increasing severity and again for the disease stage groups collapsed into benign (serous cystadenoma or endosalpingosis), low-grade [serous borderline tumors (SBT) or low-grade serous carcinoma (LGSC)] and high-grade serous carcinoma. Results: There was no loss of expression in benign serous cystadenomas (0/18). Ten percent of SBT's (2/20), 47{\%} of LGSC's (9/19), and 16{\%} of HGSC's (3/16) had loss of expression. There was a significant difference in the expression during the progression from cystadenoma to SBT to LGSC. Conclusions: Loss of Rb2/p130 expression is a rare event in benign cystadenoma. The progression to LGSC is associated with a decrease in gene expression.",
keywords = "ovarian cancer, ovary, Rb2/p130, retinoblastoma",
author = "Worley, {Michael J.} and Landen, {Charles N.} and Brian Slomovitz and Anais Malpica and Palla, {Shana L.} and Ramirez, {Pedro T.}",
year = "2010",
month = "12",
doi = "10.1097/PAI.0b013e3181e78fe0",
language = "English (US)",
volume = "18",
pages = "509--511",
journal = "Applied Immunohistochemistry and Molecular Morphology",
issn = "1541-2016",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Expression of the retinoblastoma-related gene Rb2/p130 in the pathogenesis of serous carcinoma of the ovary

AU - Worley, Michael J.

AU - Landen, Charles N.

AU - Slomovitz, Brian

AU - Malpica, Anais

AU - Palla, Shana L.

AU - Ramirez, Pedro T.

PY - 2010/12

Y1 - 2010/12

N2 - Objective: The purpose of this study was to evaluate the immunohistochemical Rb2/p130 expression in a series of benign, borderline, and malignant ovarian tumors. Study Design: Seventy-six operative specimens were analyzed. Frequencies and percents were calculated for variables by each of the 5 disease stage groups in increasing severity and again for the disease stage groups collapsed into benign (serous cystadenoma or endosalpingosis), low-grade [serous borderline tumors (SBT) or low-grade serous carcinoma (LGSC)] and high-grade serous carcinoma. Results: There was no loss of expression in benign serous cystadenomas (0/18). Ten percent of SBT's (2/20), 47% of LGSC's (9/19), and 16% of HGSC's (3/16) had loss of expression. There was a significant difference in the expression during the progression from cystadenoma to SBT to LGSC. Conclusions: Loss of Rb2/p130 expression is a rare event in benign cystadenoma. The progression to LGSC is associated with a decrease in gene expression.

AB - Objective: The purpose of this study was to evaluate the immunohistochemical Rb2/p130 expression in a series of benign, borderline, and malignant ovarian tumors. Study Design: Seventy-six operative specimens were analyzed. Frequencies and percents were calculated for variables by each of the 5 disease stage groups in increasing severity and again for the disease stage groups collapsed into benign (serous cystadenoma or endosalpingosis), low-grade [serous borderline tumors (SBT) or low-grade serous carcinoma (LGSC)] and high-grade serous carcinoma. Results: There was no loss of expression in benign serous cystadenomas (0/18). Ten percent of SBT's (2/20), 47% of LGSC's (9/19), and 16% of HGSC's (3/16) had loss of expression. There was a significant difference in the expression during the progression from cystadenoma to SBT to LGSC. Conclusions: Loss of Rb2/p130 expression is a rare event in benign cystadenoma. The progression to LGSC is associated with a decrease in gene expression.

KW - ovarian cancer

KW - ovary

KW - Rb2/p130

KW - retinoblastoma

UR - http://www.scopus.com/inward/record.url?scp=78650510964&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650510964&partnerID=8YFLogxK

U2 - 10.1097/PAI.0b013e3181e78fe0

DO - 10.1097/PAI.0b013e3181e78fe0

M3 - Article

C2 - 20661130

AN - SCOPUS:78650510964

VL - 18

SP - 509

EP - 511

JO - Applied Immunohistochemistry and Molecular Morphology

JF - Applied Immunohistochemistry and Molecular Morphology

SN - 1541-2016

IS - 6

ER -